Frontlight ResearchEarly access
CompletedNo phase
The SUN Clinical Trial (Safety Utilizing NUsurface Meniscus Implant)
Key facts
- Who runs it
- Phoenix Kinetics
- Where
- Arlington, Baton Rouge, Boulder, Denver, Greenwood, La Mesa, Long Beach, New Orleans, Phoenix, Portland, Richmond, Salt Lake City, and San Francisco, United StatesSee the 13 sites
- Trial code
- Status
- Completed
- People taking part
- 115 people enrolled
- Started
- Dec 2015
- Ended
- 29 May 2024
- Type of study
- Interventional
- Treatments tested
- NUsurface® Meniscus Implant
- Record updated
- 31 August 2026
Who can take part
- Age
- 30 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 45 criteriaShow less
Who can take part
- Had > 6 months ago a medial partial meniscectomy as confirmed by patient history and MRI
- Has a KOOS Pain of ≤ 75 (100 being the highest attainable and no pain)
- Is between age 30 and 75 years (inclusive) at the time of study treatment
- Has neutral alignment ±5º of the mechanical axis, as measured from the angle formed by a line drawn from the center of the femoral head to the medial tibial spine and a line drawn from the medial tibial spine and the center of the ankle joint
- Has ≥ 2 mm intact medial meniscal rim capable of being fitted with a NUsurface® device
- Is able to do the study required follow-up visits, questionnaires, X-rays and MRI's
- Is able to read and understand the English language if treated at a U.S. site or read and understand one of the official country languages if treated at a site Outside the U.S
- Is able and willing to understand and sign the Informed Consent Form
Who cannot take part
- Has evidence of a Outerbridge Grade IV cartilage loss on the medial tibial plateau or femoral condyle that potentially could contact a NUsurface implant (e.g., a focal lesion > 0.5 cm2 correlating to a circular defect of > 8 mm in diameter)
- Had an ACL reconstruction performed < 9 months prior to study treatment
- Decides to receive (if eligible and an option) allograft medial meniscus transplantation
- Received any type of prosthetic knee implant made of artificial non-resorbable plastic, metal or ceramic, not including the NUsurface® Meniscus Implant
- Had a previous medial femoral condyle surgery (not including microfracture) or High Tibial Osteotomy (HTO)
- Anticipates having another lower extremity surgery during the study period
- Has received any corticosteroid knee injections ≤ 3 months prior to study treatment
- Patients who are contraindicated for MRI (i.e., pacemaker, defibrillator, cochlear implants, etc.)
- Has insufficiency fractures or avascular necrosis of the medial compartment
- Has an active infection or tumor (local or systemic)
- Has any type of knee joint inflammatory disease including Sjogren's syndrome
- Has any medical condition that does not allow possible arthroscopy of the knee
- Is contraindicated for corticosteroid injections (i.e., patients with allergy to any of the components or with idiopathic thrombocytopenic purpura)
- Has ipsilateral or contralateral lower limb joint conditions that may affect ambulation or KOOS (e.g. have a leg length discrepancy > 2.5 cm [1 inch], causing a noticeable limp)
- Is mentally incapacitated (incapable of appraising or controlling conduct) or have mental disability (e.g., dementia or Alzheimer's)
- Is contraindicated for hyaluronic acid injections (i.e., patients with known hypersensitivity [allergy] to hyaluronan [sodium hyaluoronate] preparations); patients having knee joint infections or skin diseases or infections in the site of possible injections
- Has a symptomatic knee because of a tear that could be addressed by a repeat partial meniscectomy leaving > 4 mm of medial meniscus rim
- Has complete disruption of the posterior root attachment of the meniscus
- Has lateral compartment pain and Grade III or Grade IV Outerbridge cartilage score in the lateral compartment
- Has a varus or valgus knee deformity > 5º requiring a tibial or femoral osteotomy
- Has a laxity level of more than Grade II (IKDC), primary or secondary to an injury of the anterior cruciate ligament (ACL) and/or posterior cruciate ligament (PCL) and/or lateral collateral ligament (LCL) and/or medial collateral ligament (MCL)
- Has significant trochlear dysplasia, patellar instability or symptomatic patellar misalignment
- Has patellar compartment pain and Grade III or Grade IV Outerbridge cartilage score in the patellar compartment
- Compared to a normal knee, has obvious radiological evidence of medial femoral squaring, anatomical variance in the medial tibial plateau, or irregularly shaped cartilage surface
- Has a BMI > 32.5 at the start of study treatment
- Has a knee flexion contracture > 10º
- Has flexion < 90º
- Has neuropathic knee osteoarthropathy, also known as Charcot joint
- Has neurological deficit (sensory, motor, or reflex)
- Is currently involved in another investigation of the lower extremity
- Has chondrocalcinosis
- Is on immunostimulating or immunosuppressing agents
- Is a female who is lactating, expecting, or is intending to become pregnant during the study period
- Is an active smoker
- Is a prisoner
- Is a patient who has economic incentive not to improve
- Certain patient populations that are at high risk for poor healing or outcomes such as patients who have a co-morbidity that reduces life expectancy to less than 36 months
Where in United States
- Arlington Orthopedic Associates, PAArlington, United States
- Baton Rouge Orthopaedic ClinicBaton Rouge, United States
- CU Sports MedicineBoulder, United States
- Advanced Orthopaedics & Sports Medicine SpecialistsDenver, United States
- OrthoIndyGreenwood, United States
- Horizon Clinical ResearchLa Mesa, United States
- Long Beach Memorial Medical CenterLong Beach, United States
- Ochsner Sports Medicine InstituteNew Orleans, United States
- Banner-University Medical Center PhoenixPhoenix, United States
- Sports Medicine OregonPortland, United States
- OrthoVirginiaRichmond, United States
- Comprehensive Orthopaedics & Sports MedicineSalt Lake City, United States
- St. Mary's Medical CenterSan Francisco, United States
About the trial
What the trial wants to find out
The NUsurface® Meniscus Implant SUN Clinical Trial is a multi-center, single-arm, prospective, open label, non-randomized, observational clinical trial to gather safety and probable clinical benefit data on the NUsurface® Meniscus Implant in treated the target population.
The group in the trial
- NUsurface Meniscus ImplantTreatment being tested
All eligible patients will receive the NUsurface® Meniscus Implant.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The SUN Clinical Trial (Safety Utilizing NUsurface Meniscus Implant). A Multi-center, Single-arm, Prospective, Open-label, Non-randomized, Observational Clinical Study
- Record updated
- 31 August 2026